Both groups demonstrated moderate-to-severe psoriasis, as evidenced by PASI values of 19.54 ± 6.91 in the anti-IL-17 group and 17.38 ± 8.05 in the anti-IL-23 group. The gene discussed is IL17A; the disease is psoriasis.